First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

•IO based regimens are the new frontline standard for advanced NSCLC with good PS.•Predictive biomarkers are needed to improve patients' selection and outcomes.•Trials are on-going to address resistance to PD-(L)1 and CTLA-4 inhibitors. The development of PD-1, PD-L1 and CTLA-4 immune checkpoin...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-08, Vol.134, p.245-253
Main Authors: Ackermann, Christoph Jakob, Reck, Martin, Paz-Ares, Luis, Barlesi, Fabrice, Califano, Raffaele
Format: Article
Language:English
Subjects:
Advanced
Cancer
Checkpoint inhibitors
Chemotherapy
CTLA-4
First-line
Immuno-Oncology
Immunotherapy
Life Sciences
Non-Small-Cell Lung Cancer
NSCLC
PD-1
PD-L1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•IO based regimens are the new frontline standard for advanced NSCLC with good PS.•Predictive biomarkers are needed to improve patients' selection and outcomes.•Trials are on-going to address resistance to PD-(L)1 and CTLA-4 inhibitors. The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2019.06.007